Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

6 ArticlesBIOCON

1 / 1

Earnings Report: 3QFY17 : 495 Companies Till Now With Management Comments

Here is a quick summary of the third quarter financial results for all the companies announced till date. For some companies, management comments have been ...

2016 in Review: The Top 10 Large Cap Performers!

As part of our year-end piece, we look at the Top 10 Large-cap performers for 2016 (ending 23-Dec). You can catch our earlier series here: 2015 in Review: ...

EMA agrees to review Mylan and Biocon’s Regulatory Submission for proposed biosimilar Pegfilgrastim

European Medical Agency has accepted the submission for the review of the biosimilar Pegfilgrastim co-developed by Mylan & Biocon. The proposed ...

Biocon receives approval from Drug Controller General of India for the first ever clinical trial of a siRNA therapy

Biocon – one of the largest emerging global biopharmaceutical enterprise (has a rich pipeline of Biosimilars and Novel Biologics at various stages of ...

March 2016 Results – Alembic Pharmaceuticals, Bharti Airtel, Yes Bank and more

Q4 Results are out! As the companies line up to disclose their performance report, we bring you a daily summary of the previous days results. Here is a quick ...

Biocon Rumours of Oral Insulin Deal Push Up Stock 10%

Biocon has been rumoured to have serious developments in its oral insulin product, and in talks with a few large pharma companies to license the product. This ...